Meta-analysis: Effectiveness of long- and short-term albendazole therapy for intraparenchymal neurocysticercosis

Descripción del Articulo

Objective: To determine the effectiveness of long- and short-term albendazole therapy in adults and children with cystic and transitional parenchymal neurocysticercosis confirmed by neuroimaging. Materials and methods: A meta-analysis was performed using clinical trials from MEDLINE and LILACS with...

Descripción completa

Detalles Bibliográficos
Autor: Jerves Serrano, Teodoro Edmundo
Formato: artículo
Fecha de Publicación:2018
Institución:Universidad de San Martín de Porres
Repositorio:Horizonte médico
Lenguaje:español
OAI Identifier:oai:horizontemedico.usmp.edu.pe:article/705
Enlace del recurso:https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/705
Nivel de acceso:acceso abierto
Materia:Neurocysticercosis
Albendazole
Effectiveness
Therapy
Neurocisticercosis
Albendazol
Efectividad
Tratamiento
id REVHM_eb765409556e459a67f1f5aa5dfed3a1
oai_identifier_str oai:horizontemedico.usmp.edu.pe:article/705
network_acronym_str REVHM
network_name_str Horizonte médico
repository_id_str
dc.title.none.fl_str_mv Meta-analysis: Effectiveness of long- and short-term albendazole therapy for intraparenchymal neurocysticercosis
Metaanálisis: efectividad del tratamiento a largo y corto plazo con albendazol para la neurocisticercosis intraparenquimatosa
title Meta-analysis: Effectiveness of long- and short-term albendazole therapy for intraparenchymal neurocysticercosis
spellingShingle Meta-analysis: Effectiveness of long- and short-term albendazole therapy for intraparenchymal neurocysticercosis
Jerves Serrano, Teodoro Edmundo
Neurocysticercosis
Albendazole
Effectiveness
Therapy
Neurocisticercosis
Albendazol
Efectividad
Tratamiento
title_short Meta-analysis: Effectiveness of long- and short-term albendazole therapy for intraparenchymal neurocysticercosis
title_full Meta-analysis: Effectiveness of long- and short-term albendazole therapy for intraparenchymal neurocysticercosis
title_fullStr Meta-analysis: Effectiveness of long- and short-term albendazole therapy for intraparenchymal neurocysticercosis
title_full_unstemmed Meta-analysis: Effectiveness of long- and short-term albendazole therapy for intraparenchymal neurocysticercosis
title_sort Meta-analysis: Effectiveness of long- and short-term albendazole therapy for intraparenchymal neurocysticercosis
dc.creator.none.fl_str_mv Jerves Serrano, Teodoro Edmundo
author Jerves Serrano, Teodoro Edmundo
author_facet Jerves Serrano, Teodoro Edmundo
author_role author
dc.subject.none.fl_str_mv Neurocysticercosis
Albendazole
Effectiveness
Therapy
Neurocisticercosis
Albendazol
Efectividad
Tratamiento
topic Neurocysticercosis
Albendazole
Effectiveness
Therapy
Neurocisticercosis
Albendazol
Efectividad
Tratamiento
description Objective: To determine the effectiveness of long- and short-term albendazole therapy in adults and children with cystic and transitional parenchymal neurocysticercosis confirmed by neuroimaging. Materials and methods: A meta-analysis was performed using clinical trials from MEDLINE and LILACS with a Jadad score > 2. Additional studies were not found on ClinicalTrials.gov and ResearchGate. The main endpoint was the persistence of radiological lesions and the secondary endpoint was the presence of adverse effects. Pooled relative risks (RR) and 95 % confidence intervals were calculated for both endpoints using the Mantel-Haenszel fixed-effects model. The analysis was conducted using software Stata 11. Heterogeneity was assessed by chi-square test and a value of p < 0.10 was considered statistically significant. Publication bias was estimated by sensitivity analysis and Egger’s test. Results: Four studies were included. There was no difference between long- and short-term albendazole therapies for neurocysticercosis. Pooled RR of the persistence of radiological lesions after short-term vs. long-term therapy was 1.05 (95 % CI 0.72-1.54). Mantel-Haenszel test showed a p-value of 0.789. Moreover, both the sensitivity analysis and Egger’s test supported the absence of publication bias. No significant difference was noticed regarding the adverse effects. Conclusions: Evidence suggests that there is no difference between short- and long-term therapies for single transitional parenchymal lesions; therefore short-term therapy may be used effectively.
publishDate 2018
dc.date.none.fl_str_mv 2018-03-31
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/705
10.24265/horizmed.2018.v18n1.06
url https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/705
identifier_str_mv 10.24265/horizmed.2018.v18n1.06
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/705/471
https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/705/472
dc.rights.none.fl_str_mv Derechos de autor 2018 Horizonte Médico (Lima)
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2018 Horizonte Médico (Lima)
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad de San Martín de Porres. Facultad de Medicina Humana
publisher.none.fl_str_mv Universidad de San Martín de Porres. Facultad de Medicina Humana
dc.source.none.fl_str_mv Horizonte Médico (Lima); Vol. 18 No. 1 (2018): January - March; 35-41
Horizonte Médico (Lima); Vol. 18 Núm. 1 (2018): Enero - Marzo; 35-41
Horizonte Médico (Lima); v. 18 n. 1 (2018): Enero - Marzo; 35-41
2227-3530
1727-558X
10.24265/horizmed.2018.v18n1
reponame:Horizonte médico
instname:Universidad de San Martín de Porres
instacron:USMP
instname_str Universidad de San Martín de Porres
instacron_str USMP
institution USMP
reponame_str Horizonte médico
collection Horizonte médico
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1846623139093544960
spelling Meta-analysis: Effectiveness of long- and short-term albendazole therapy for intraparenchymal neurocysticercosisMetaanálisis: efectividad del tratamiento a largo y corto plazo con albendazol para la neurocisticercosis intraparenquimatosaJerves Serrano, Teodoro EdmundoNeurocysticercosisAlbendazoleEffectivenessTherapyNeurocisticercosis AlbendazolEfectividadTratamientoObjective: To determine the effectiveness of long- and short-term albendazole therapy in adults and children with cystic and transitional parenchymal neurocysticercosis confirmed by neuroimaging. Materials and methods: A meta-analysis was performed using clinical trials from MEDLINE and LILACS with a Jadad score > 2. Additional studies were not found on ClinicalTrials.gov and ResearchGate. The main endpoint was the persistence of radiological lesions and the secondary endpoint was the presence of adverse effects. Pooled relative risks (RR) and 95 % confidence intervals were calculated for both endpoints using the Mantel-Haenszel fixed-effects model. The analysis was conducted using software Stata 11. Heterogeneity was assessed by chi-square test and a value of p < 0.10 was considered statistically significant. Publication bias was estimated by sensitivity analysis and Egger’s test. Results: Four studies were included. There was no difference between long- and short-term albendazole therapies for neurocysticercosis. Pooled RR of the persistence of radiological lesions after short-term vs. long-term therapy was 1.05 (95 % CI 0.72-1.54). Mantel-Haenszel test showed a p-value of 0.789. Moreover, both the sensitivity analysis and Egger’s test supported the absence of publication bias. No significant difference was noticed regarding the adverse effects. Conclusions: Evidence suggests that there is no difference between short- and long-term therapies for single transitional parenchymal lesions; therefore short-term therapy may be used effectively.Objetivo: Determinar la efectividad del tratamiento con Albendazol de larga y corta duración en adultos y niños con neurocisticercosis parenquimatosa cística o transicional, verificado por neuroimagen. Materiales y métodos: Un metaanálisis fue realizado analizando los ensayos clínicos de Medline y LILACS con un puntaje de Jadad > 2. Estudios adicionales no fueron identificados en Clinicaltrials.gov y Researchgate. La variable principal fue la persistencia de las lesiones radiológicas y la secundaria los efectos adversos. El RR acumulado y un intervalo de confianza del 95 % fueron calculados para las dos variables usando el modelo de efectos fijos de Mantel-Haenszel. El análisis fue realizado en el programa Stata 11. La heterogeneidad fue evaluada con el prueba chi cuadrado, una p < 0,10 fue considerada estadísticamente significativa. El sesgo de publicación fue evaluado por el análisis de sensibilidad y la prueba de Egger. Resultados: Cuatro estudios fueron incluidos. No hay diferencia entre la terapia de larga y corta duración para la neurocisticercosis. El RR acumulado de la persistencia de lesiones radiológicas después del tratamiento a corto plazo en comparación al de largo plazo fue 1,05 (IC 95 % 0,72-1,54). La prueba de Mantel-Haenszel demostró un valor de p de 0,789. Además, ambos, el análisis de sensibilidad y la prueba de Egger apoyaron la ausencia de sesgo de publicación. No hubo diferencia significativa respecto a los efectos adversos. Conclusiones: La evidencia sugiere que no hay diferencia entre el tratamiento de corto y largo plazo para las lesiones parenquimatosas transicionales únicas, por lo que el tratamiento de corto plazo puede ser usado efectivamente.Universidad de San Martín de Porres. Facultad de Medicina Humana2018-03-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/70510.24265/horizmed.2018.v18n1.06Horizonte Médico (Lima); Vol. 18 No. 1 (2018): January - March; 35-41Horizonte Médico (Lima); Vol. 18 Núm. 1 (2018): Enero - Marzo; 35-41Horizonte Médico (Lima); v. 18 n. 1 (2018): Enero - Marzo; 35-412227-35301727-558X10.24265/horizmed.2018.v18n1reponame:Horizonte médicoinstname:Universidad de San Martín de Porresinstacron:USMPspahttps://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/705/471https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/705/472Derechos de autor 2018 Horizonte Médico (Lima)https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:horizontemedico.usmp.edu.pe:article/7052019-07-15T00:26:28Z
score 13.135628
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).